Press release
Metastatic Liver Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND
Stay ahead with the latest insights! Download DelveInsight's comprehensive Metastatic Liver Cancer Pipeline Report to explore emerging therapies, key Metastatic Liver Cancer Companies, and future Metastatic Liver Cancer treatment landscapes @ Metastatic Liver Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Metastatic Liver Cancer Pipeline Report
* In March 2025, Akeso announced a phase II Study to Evaluate the Efficacy and Safety of AK104 Plus Lenvatinib and TACE in the Treatment of Unresectable, Non-metastatic Hepatocellular Carcinoma.
* In March 2025, BeiGene conducted a study was to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) by central site imaging facility per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
* In February 2025:- Alethia Biotherapeutics:- This Phase II study will recruit 17 colorectal cancerpatients with liver-dominant metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks for the first 4 cycles followed by liver metastases resection surgery with or without primary cancer resection. One cycle of treatment will consist of 14 days (2 weeks).
* In February 2025:- Medivir :- This is an open-label, multicentre dose escalation/expansion study to assess safety and tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a tyrosine kinase inhibitor used as a standard of care for the treatment of HCC or 2) pembrolizumab, a PD-1 inhibitor. The monotherapy parts of the study will include patients with various solid tumours that have spread to the liver, or alternatively originating in the liver. Evaluations of MIV-818 in combination with lenvatinib or pembrolizumab will only include patients with HCC.
* In February 2025:- Kamya Sankar :-This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases.
* In February 2025:- Tango Therapeutics Inc.:- This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
* In February 2025:- Bristol-Myers Squibb:- The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).
* DelveInsight's Metastatic Liver Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Metastatic Liver Cancer treatment.
* The leading Metastatic Liver Cancer Companies such as Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim , and others.
* Promising Metastatic Liver Cancer Therapies such as ThermoDox Registered (LTLD), NV1020, Combretastatin A1 Diphosphate (OXi4503), Talaporfin sodium (LS11), CRS-100, EndoTAG Registered -1, AV-299, RO7119929, Tocilizumab, and others.
Discover how the Metastatic Liver Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Metastatic Liver Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Liver Cancer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Liver Cancer Emerging Drugs Profile
* exoASO STAT6: Codiak BioSciences
exoASO Trademark -STAT6 is an exosome therapeutic candidate engineered using our engEx Trademark Platform to overexpress Codiak's novel protein scaffold, PTGFRN, to selectively target uptake in M2 polarized tumor-associated macrophages. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.
* STP 705: Sirnaomics
STP705, is a dual TGF-Ss1/COX-2 inhibitor. TGF-Ss1 and COX-2 are well-validated gatekeeper targets for oncology and fibrosis disease drug development. STP705 leverages our locally administered PNP formulation for direct administration to diseased tissue. STP705 has received U.S. orphan drug designation for the treatment of certain hepatocellular carcinomas and liver fibrosis, including: primary sclerosing cholangitis (PSC), cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.
* ONCR 177: Oncorus
ONCR-177, our lead product candidate, is an intratumorally administered Herpes Simplex Virus (HSV) viral immunotherapy for the treatment of multiple solid tumor cancers. ONCR-177 fights tumors through multiple mechanisms, including inherent oncolytic activity, immune stimulation elicited by viral infection and the expression of five transgenes (IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.
The Metastatic Liver Cancer pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Liver Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Liver Cancer Treatment.
* Metastatic Liver Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Metastatic Liver Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Liver Cancer market.
Get a detailed analysis of the latest innovations in the Metastatic Liver Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Metastatic Liver Cancer Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Liver Cancer Companies
Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
Metastatic-Liver-Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Metastatic Liver Cancer Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming Metastatic Liver Cancer Therapies and key Metastatic Liver Cancer Developments @ Metastatic Liver Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Metastatic Liver Cancer Pipeline Report
* Coverage- Global
* Metastatic Liver Cancer Companies- Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
* Metastatic Liver Cancer Therapies- ThermoDox Registered (LTLD), NV1020, Combretastatin A1 Diphosphate (OXi4503), Talaporfin sodium (LS11), CRS-100, EndoTAG Registered -1, AV-299, RO7119929, Tocilizumab , and others.
* Metastatic Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Metastatic Liver Cancer drug development? Find out in DelveInsight's exclusive Metastatic Liver Cancer Pipeline Report-access it now! @ Metastatic Liver Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Metastatic-Liver-Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic-Liver-Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name :Company Name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name :Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ONCR 177: Oncorus
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name :Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic-Liver-Cancer Key Companies
* Metastatic-Liver-Cancer Key Products
* Metastatic-Liver-Cancer- Unmet Needs
* Metastatic-Liver-Cancer- Market Drivers and Barriers
* Metastatic-Liver-Cancer- Future Perspectives and Conclusion
* Metastatic-Liver-Cancer Analyst Views
* Metastatic-Liver-Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-liver-cancer-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Liver Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND here
News-ID: 3925143 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Metastatic
Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025?
The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth?
The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
